These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24831281)

  • 1. Pharmacodynamic biomarkers: falling short of the mark?
    Gainor JF; Longo DL; Chabner BA
    Clin Cancer Res; 2014 May; 20(10):2587-94. PubMed ID: 24831281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular predictors of response to chemotherapy in non-small cell lung cancer.
    Andrews J; Yeh P; Pao W; Horn L
    Cancer J; 2011; 17(2):104-13. PubMed ID: 21427554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early oncology clinical trial design in the era of molecular-targeted agents.
    Brunetto AT; Kristeleit RS; de Bono JS
    Future Oncol; 2010 Aug; 6(8):1339-52. PubMed ID: 20799878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular predictors of chemotherapy response in non-small-cell lung cancer.
    Gray J; Simon G; Bepler G
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):545-9. PubMed ID: 17428174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
    Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.
    Garcia VM; Cassier PA; de Bono J
    Cancer Discov; 2011 Aug; 1(3):207-12. PubMed ID: 22586572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Met pathway in lung cancer.
    Belalcazar A; Azaña D; Perez CA; Raez LE; Santos ES
    Expert Rev Anticancer Ther; 2012 Apr; 12(4):519-28. PubMed ID: 22500688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers.
    Singh N; Bal A; Aggarwal AN; Das A; Behera D
    Future Oncol; 2010 May; 6(5):741-67. PubMed ID: 20465389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emerging role of biomarkers in advanced non-small-cell lung cancer.
    Socinski MA
    Clin Lung Cancer; 2010 May; 11(3):149-59. PubMed ID: 20439190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
    Sequist LV; Bell DW; Lynch TJ; Haber DA
    J Clin Oncol; 2007 Feb; 25(5):587-95. PubMed ID: 17290067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing biomarker-specific end points in lung cancer clinical trials.
    Neal JW; Gainor JF; Shaw AT
    Nat Rev Clin Oncol; 2015 Mar; 12(3):135-46. PubMed ID: 25533947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents.
    Le Tourneau C; Vidal L; Siu LL
    Drug Resist Updat; 2008 Jun; 11(3):99-109. PubMed ID: 18515176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue sampling in lung cancer: a review in light of the MERIT experience.
    Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
    Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.